Showing results (201-210 of 481) with videos related to
Sort By:
Pageof 49
Journal of the American College of Cardiology|June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialDavid M Charytan, Marc S Sabatine, Terje R Pedersen, et al.NEJM Evidence|December 24, 2024
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabAndré Zimerman, Michelle L O'Donoghue, Xinhui Ran, et al.The New England Journal of Medicine|November 27, 2009
A sensitive cardiac troponin T assay in stable coronary artery diseaseTorbjørn Omland, James A de Lemos, Marc S Sabatine, et al.Journal of the American College of Cardiology|June 11, 2011
Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling studyAslan T Turer, Tayo A Addo, Justin L Martin, et al.European Heart Journal. Cardiovascular Pharmacotherapy|January 25, 2021
Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b designMarc P Bonaca, Richard T George, David A Morrow, et al.American Heart Journal|December 31, 2023
Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trialErin A Bohula, Nicholas A Marston, Andrea Ruzza, et al.Stroke|April 22, 2020
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable AtherosclerosisRobert P Giugliano, Terje R Pedersen, Jeffrey L Saver, et al.Circulation. Cardiovascular Interventions|January 12, 2021
Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO TrialJean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, et al.Diabetes Care|August 9, 2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 DiabetesFilipe A Moura, David D Berg, Andrea Bellavia, et al.The New England Journal of Medicine|March 17, 2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular eventsMarc S Sabatine, Robert P Giugliano, Stephen D Wiviott, et al.Pageof 49